Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy (Q37867099)

24 August 2017

1 reference

title

Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy (English)

1 reference

24 August 2017

1 reference

1 reference

Curtis Cooper

1

1 reference

PubMed ID

21506639

24 August 2017

David Mackie

series ordinal

2

1 reference

PubMed ID

21506639

24 August 2017

language of work or name

1 reference

1 April 2011

1 reference

Expert Review of Vaccines

24 August 2017

1 reference

24 August 2017

10

1 reference

24 August 2017

4

1 reference

24 August 2017

417-427

1 reference

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

24 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Epidemiology of hepatitis B and C viruses: a global overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Hepatitis B virus infection: epidemiology and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Hepatitis B vaccination strategies tailored to different endemicity levels: some considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Management of acute hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Toward elimination and eradication of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Recombinant hepatitis B vaccination in renal failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Infections, vaccines and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

AM3 inhibits HBV replication through activation of peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Immunostimulatory DNA as a vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

A hepatitis B vaccine formulated with a novel adjuvant system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

The ventilatory response to hypoxia: how much is good for a mountaineer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.162

21 January 2018

Identifiers

DOI

10.1586/ERV.10.162

1 reference

24 August 2017

1 reference

PubMed ID

21506639